STADA: Teriparatide-Biosimilar Movymia® for treatment of osteoporosis launched in 24 countries
08/20/2019 - 09.31 AM . Press Release
- STADA's Movymia® is a cost-effective alternative to Forsteo®.
- The sales volume of the reference product was almost EUR 250 million in the last 12 months in Europe (IQVIA MAT/3/19).
- CEO Peter Goldschmidt: "The launch of Movymia® is another important expansion of our biosimilar portfolio in Europe."
Bad Vilbel, August 20, 2019 – On time for patent expiration of the reference product Forsteo®, STADA is gradually launching the biosimilar Movymia® as a cost-effective alternative in 24 countries starting at the end of August. Forsteo® had a sales volume of almost EUR 250 million over the last 12 months in Europe. Teriparatide is approved for the treatment of osteoporosis and is the only active ingredient approved for osteoanabolic therapy.
"The launch of Movymia® is another important step in the expansion of our biosimilar portfolio in Europe. With this product, we offer patients a cost-effective alternative to the reference product with the same therapeutic safety and efficacy", explains STADA CEO Peter Goldschmidt the importance of the product launch for STADA.
Movymia® is injected using a re-fillable, multidose injection device called Movymia® Pen. The pen is used during the entire treatment period.
A biosimilar is a pharmaceutical product manufactured by using biotechnology with a protein as active ingredient developed with the aim of being comparable to an existing biological pharmaceutical product (the “reference pharmaceutical product”). There are no significant differences in quality, safety and effectiveness between biosimilars and reference pharmaceutical products.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press(at)stada.de
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir(at)stada.de
Or visit us on the Internet at www.stada.com/investor-relations